Skip to main content
Top
Published in: Respiratory Research 1/2014

Open Access 01-12-2014 | Research

Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD

Authors: Poornima Gopal, Niki L Reynaert, Jean L J M Scheijen, Casper G Schalkwijk, Frits M E Franssen, Emiel F M Wouters, Erica P A Rutten

Published in: Respiratory Research | Issue 1/2014

Login to get access

Abstract

Rationale

Plasma soluble Receptor for Advanced Glycation End Product (sRAGE) is considered as a biomarker in COPD. The contribution of endogenous sRAGE (esRAGE) to the pool of plasma sRAGE and the implication of both markers in COPD pathogenesis is however not clear yet. The aim of the current study was therefore to measure plasma levels of esRAGE comparative to total sRAGE in patients with COPD and a control group. Further, we established the relations of esRAGE and total sRAGE with disease specific characteristics such as lung function and DLCO, and with different circulating AGEs.

Methods

Plasma levels of esRAGE and sRAGE were measured in an 88 patients with COPD and in 55 healthy controls. FEV1 (%predicted) and FEV1/VC (%) were measured in both groups; DLCO (%predicted) was measured in patients only. In this study population we previously reported that the AGE Nϵ-(carboxymethyl) lysine (CML) was decreased, Nϵ-(carboxyethyl) lysine (CEL) increased and pentosidine was not different in plasma of COPD patients compared to controls.

Results

Plasma esRAGE (COPD: 533.9 ± 412.4, Controls: 848.7 ± 690.3 pg/ml; p = 0.000) was decreased in COPD compared to controls. No significant correlations were observed between plasma esRAGE levels and lung function parameters or plasma AGEs. A positive correlation was present between esRAGE and total sRAGE levels in the circulation. Confirming previous findings, total sRAGE (COPD: 512.6 ± 403.8, Controls: 1834 ± 804.2 pg/ml; p < 0.001) was lower in patients compared to controls and was positively correlated FEV1 (r = 0.235, p = 0.032), FEV1/VC (r = 0.218, p = 0.047), and DLCO (r = 0.308, p = 0.006). sRAGE furthermore did show a significant positive association with CML (r = 0.321, p = 0.003).

Conclusion

Although plasma esRAGE is decreased in COPD patients compared to controls, only total sRAGE showed a significant and independent association with FEV1, FEV1/VC and DLCO, indicating that total sRAGE but not esRAGE may serve as marker of COPD disease state and severity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M: Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case–control study. Respir Res. 2011, 12: 37-10.1186/1465-9921-12-37.PubMedPubMedCentralCrossRef Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M: Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case–control study. Respir Res. 2011, 12: 37-10.1186/1465-9921-12-37.PubMedPubMedCentralCrossRef
2.
go back to reference Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PMA, Celli B, Crim C, Duvoix A, et al: The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med. 2013, 1: 129-136. 10.1016/S2213-2600(13)70006-7.PubMedCrossRef Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PMA, Celli B, Crim C, Duvoix A, et al: The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med. 2013, 1: 129-136. 10.1016/S2213-2600(13)70006-7.PubMedCrossRef
3.
go back to reference Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992, 267: 14998-15004.PubMed Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992, 267: 14998-15004.PubMed
4.
go back to reference Kumano-Kuramochi M, Ohnishi-Kameyama M, Xie Q, Niimi S, Kubota F, Komba S, Machida S: Minimum stable structure of the receptor for advanced glycation end product possesses multi ligand binding ability. Biochem Biophys Res Commun. 2009, 386: 130-134. 10.1016/j.bbrc.2009.05.142.PubMedCrossRef Kumano-Kuramochi M, Ohnishi-Kameyama M, Xie Q, Niimi S, Kubota F, Komba S, Machida S: Minimum stable structure of the receptor for advanced glycation end product possesses multi ligand binding ability. Biochem Biophys Res Commun. 2009, 386: 130-134. 10.1016/j.bbrc.2009.05.142.PubMedCrossRef
5.
go back to reference Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, Grant PJ, Schmidt AM: Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008, 22: 1572-1580.PubMedCrossRef Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, Grant PJ, Schmidt AM: Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008, 22: 1572-1580.PubMedCrossRef
6.
go back to reference Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008, 22: 3716-3727. 10.1096/fj.08-109033.PubMedCrossRef Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008, 22: 3716-3727. 10.1096/fj.08-109033.PubMedCrossRef
7.
go back to reference Yamakawa N, Uchida T, Matthay MA, Makita K: Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2011, 300: L516-L525. 10.1152/ajplung.00118.2010.PubMedPubMedCentralCrossRef Yamakawa N, Uchida T, Matthay MA, Makita K: Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2011, 300: L516-L525. 10.1152/ajplung.00118.2010.PubMedPubMedCentralCrossRef
8.
go back to reference Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem. 2000, 275: 25781-25790. 10.1074/jbc.M001235200.PubMedCrossRef Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem. 2000, 275: 25781-25790. 10.1074/jbc.M001235200.PubMedCrossRef
9.
go back to reference Gopal P, Reynaert NL, Scheijen JL, Engelen L, Schalkwijk CG, Franssen FM, Wouters EF, Rutten EP: Plasma advanced glycation end-products and skin autofluorescence are increased in COPD. Euro Resp J. 2014, 43 (2): 430-438. 10.1183/09031936.00135312.CrossRef Gopal P, Reynaert NL, Scheijen JL, Engelen L, Schalkwijk CG, Franssen FM, Wouters EF, Rutten EP: Plasma advanced glycation end-products and skin autofluorescence are increased in COPD. Euro Resp J. 2014, 43 (2): 430-438. 10.1183/09031936.00135312.CrossRef
10.
go back to reference Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW: Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J. 2011, 37: 516-522. 10.1183/09031936.00029310.PubMedCrossRef Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW: Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J. 2011, 37: 516-522. 10.1183/09031936.00029310.PubMedCrossRef
11.
go back to reference Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H, Kourteva G, Bitter H, Pillai SG, Visvanathan S, et al: Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One. 2012, 7: e38629-10.1371/journal.pone.0038629.PubMedPubMedCentralCrossRef Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H, Kourteva G, Bitter H, Pillai SG, Visvanathan S, et al: Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One. 2012, 7: e38629-10.1371/journal.pone.0038629.PubMedPubMedCentralCrossRef
12.
go back to reference Wu L, Ma L, Nicholson LF, Black PN: Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med. 2011, 105: 329-336. 10.1016/j.rmed.2010.11.001.PubMedCrossRef Wu L, Ma L, Nicholson LF, Black PN: Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med. 2011, 105: 329-336. 10.1016/j.rmed.2010.11.001.PubMedCrossRef
13.
go back to reference Sukkar MB, Wood LG, Tooze M, Simpson JL, McDonald VM, Gibson PG, Wark PA: Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J. 2012, 39: 721-729. 10.1183/09031936.00022011.PubMedCrossRef Sukkar MB, Wood LG, Tooze M, Simpson JL, McDonald VM, Gibson PG, Wark PA: Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J. 2012, 39: 721-729. 10.1183/09031936.00022011.PubMedCrossRef
14.
go back to reference Gelb AF, Gold WM, Wright RR, Bruch HR, Nadel JA: Physiologic diagnosis of subclinical emphysema. Am Rev Respir Dis. 1973, 107: 50-63.PubMedCrossRef Gelb AF, Gold WM, Wright RR, Bruch HR, Nadel JA: Physiologic diagnosis of subclinical emphysema. Am Rev Respir Dis. 1973, 107: 50-63.PubMedCrossRef
15.
go back to reference Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176: 532-555. 10.1164/rccm.200703-456SO.PubMedCrossRef Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176: 532-555. 10.1164/rccm.200703-456SO.PubMedCrossRef
16.
go back to reference Thurlbeck WM: A pathologist looks at respiratory failure due to obstructive lung disease. Chest. 1970, 58 (2): 408+-PubMedCrossRef Thurlbeck WM: A pathologist looks at respiratory failure due to obstructive lung disease. Chest. 1970, 58 (2): 408+-PubMedCrossRef
17.
go back to reference Clausen JL, Coates AL, Quanjer PH: Measurement of lung volumes in humans: review and recommendations from an ATS/ERS workshop. Eur Respir J. 1997, 10: 1205-1206. 10.1183/09031936.97.10061205.PubMedCrossRef Clausen JL, Coates AL, Quanjer PH: Measurement of lung volumes in humans: review and recommendations from an ATS/ERS workshop. Eur Respir J. 1997, 10: 1205-1206. 10.1183/09031936.97.10061205.PubMedCrossRef
18.
go back to reference Hanssen NM, Engelen L, Ferreira I, Scheijen JL, Huijberts MS, Van Greevenbroek MM, van der Kallen CJ, Dekker JM, Nijpels G, Stehouwer CD, Schalkwijk CG: Plasma levels of advanced glycation endproducts N{epsilon}-(carboxymethyl)lysine, N{epsilon}-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the HOORN and CODAM studies. J Clin Endocrinol Metab. 2013, 98: E1369-E1373. 10.1210/jc.2013-1068.PubMedCrossRef Hanssen NM, Engelen L, Ferreira I, Scheijen JL, Huijberts MS, Van Greevenbroek MM, van der Kallen CJ, Dekker JM, Nijpels G, Stehouwer CD, Schalkwijk CG: Plasma levels of advanced glycation endproducts N{epsilon}-(carboxymethyl)lysine, N{epsilon}-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the HOORN and CODAM studies. J Clin Endocrinol Metab. 2013, 98: E1369-E1373. 10.1210/jc.2013-1068.PubMedCrossRef
19.
go back to reference Scheijen JL, van de Waarenburg MP, Stehouwer CD, Schalkwijk CG: Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2009, 877: 610-614. 10.1016/j.jchromb.2009.01.022.PubMedCrossRef Scheijen JL, van de Waarenburg MP, Stehouwer CD, Schalkwijk CG: Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2009, 877: 610-614. 10.1016/j.jchromb.2009.01.022.PubMedCrossRef
20.
go back to reference Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16: 31-41. 10.1159/000180580.PubMedCrossRef Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16: 31-41. 10.1159/000180580.PubMedCrossRef
21.
go back to reference Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, Nawroth PP, Bierhaus A, Postina R: Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem. 2008, 283: 35507-35516. 10.1074/jbc.M806948200.PubMedCrossRef Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, Nawroth PP, Bierhaus A, Postina R: Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem. 2008, 283: 35507-35516. 10.1074/jbc.M806948200.PubMedCrossRef
22.
go back to reference Betsuyaku T, Nishimura M, Takeyabu K, Tanino M, Venge P, Xu S, Kawakami Y: Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med. 1999, 159: 1985-1991. 10.1164/ajrccm.159.6.9809043.PubMedCrossRef Betsuyaku T, Nishimura M, Takeyabu K, Tanino M, Venge P, Xu S, Kawakami Y: Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med. 1999, 159: 1985-1991. 10.1164/ajrccm.159.6.9809043.PubMedCrossRef
23.
go back to reference Finlay GA, Russell KJ, McMahon KJ, D’Arcy EM, Masterson JB, FitzGerald MX, O’Connor CM: Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax. 1997, 52: 502-506. 10.1136/thx.52.6.502.PubMedPubMedCentralCrossRef Finlay GA, Russell KJ, McMahon KJ, D’Arcy EM, Masterson JB, FitzGerald MX, O’Connor CM: Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax. 1997, 52: 502-506. 10.1136/thx.52.6.502.PubMedPubMedCentralCrossRef
24.
go back to reference Higashimoto Y, Yamagata Y, Iwata T, Okada M, Ishiguchi T, Sato H, Masuda M, Itoh H: Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J. 2005, 25: 885-890. 10.1183/09031936.05.00092804.PubMedCrossRef Higashimoto Y, Yamagata Y, Iwata T, Okada M, Ishiguchi T, Sato H, Masuda M, Itoh H: Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J. 2005, 25: 885-890. 10.1183/09031936.05.00092804.PubMedCrossRef
25.
go back to reference Gaens KH, Ferreira I, van der Kallen CJ, Van Greevenbroek MM, Blaak EE, Feskens EJ, Dekker JM, Nijpels G, Heine RJ, Hart LM T, et al: Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab. 2009, 94: 5174-5180. 10.1210/jc.2009-1067.PubMedCrossRef Gaens KH, Ferreira I, van der Kallen CJ, Van Greevenbroek MM, Blaak EE, Feskens EJ, Dekker JM, Nijpels G, Heine RJ, Hart LM T, et al: Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab. 2009, 94: 5174-5180. 10.1210/jc.2009-1067.PubMedCrossRef
26.
go back to reference Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, et al: Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 2013, 188 (8): 948-957. 10.1164/rccm.201302-0247OC.PubMedCrossRef Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, et al: Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 2013, 188 (8): 948-957. 10.1164/rccm.201302-0247OC.PubMedCrossRef
27.
go back to reference Peng WH, Lu L, Wang LJ, Yan XX, Chen QJ, Zhang Q, Zhang RY, Shen WF: RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus. Arch Med Res. 2009, 40: 393-398. 10.1016/j.arcmed.2009.06.008.PubMedCrossRef Peng WH, Lu L, Wang LJ, Yan XX, Chen QJ, Zhang Q, Zhang RY, Shen WF: RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus. Arch Med Res. 2009, 40: 393-398. 10.1016/j.arcmed.2009.06.008.PubMedCrossRef
28.
go back to reference Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M, Dombret MC, Sims GP, Kolbeck R, Coyle AJ, et al: Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010, 181: 917-927. 10.1164/rccm.200903-0340OC.PubMedCrossRef Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M, Dombret MC, Sims GP, Kolbeck R, Coyle AJ, et al: Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010, 181: 917-927. 10.1164/rccm.200903-0340OC.PubMedCrossRef
29.
go back to reference Boschetto P, Campo I, Stendardo M: Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur J Clin Invest. 2013, 43: 562-569. 10.1111/eci.12079.PubMedCrossRef Boschetto P, Campo I, Stendardo M: Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur J Clin Invest. 2013, 43: 562-569. 10.1111/eci.12079.PubMedCrossRef
30.
go back to reference Gopal P, Rutten EP, Dentener MA, Wouters EF, Reynaert NL: Decreased plasma sRAGE levels in COPD: influence of oxygen therapy. Eur J Clin Invest. 2012, 42: 807-814. 10.1111/j.1365-2362.2012.02646.x.PubMedCrossRef Gopal P, Rutten EP, Dentener MA, Wouters EF, Reynaert NL: Decreased plasma sRAGE levels in COPD: influence of oxygen therapy. Eur J Clin Invest. 2012, 42: 807-814. 10.1111/j.1365-2362.2012.02646.x.PubMedCrossRef
31.
go back to reference Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, et al: Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with ager genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013, 188: 948-957. 10.1164/rccm.201302-0247OC.PubMedCrossRef Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, et al: Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with ager genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013, 188: 948-957. 10.1164/rccm.201302-0247OC.PubMedCrossRef
32.
go back to reference Hou C, Zhao H, Liu L, Li W, Zhou X, Lv Y, Shen X, Liang Z, Cai S, Zou F: High mobility group protein B1 (HMGB1) in Asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol Med. 2011, 17: 807-815.PubMedPubMedCentralCrossRef Hou C, Zhao H, Liu L, Li W, Zhou X, Lv Y, Shen X, Liang Z, Cai S, Zou F: High mobility group protein B1 (HMGB1) in Asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol Med. 2011, 17: 807-815.PubMedPubMedCentralCrossRef
33.
go back to reference Schleicher E, Friess U: Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl. 2007, S17: 26- Schleicher E, Friess U: Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl. 2007, S17: 26-
34.
go back to reference Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Takano Y, Yamamoto H, Yamamoto Y: Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol. 2005, 18: 1385-1396. 10.1038/modpathol.3800450.PubMedCrossRef Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Takano Y, Yamamoto H, Yamamoto Y: Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol. 2005, 18: 1385-1396. 10.1038/modpathol.3800450.PubMedCrossRef
35.
go back to reference Koyama H, Shoji T, Fukumoto S, Shinohara K, Emoto M, Mori K, Tahara H, Ishimura E, Kakiya R, Tabata T, et al: Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol. 2007, 27: 147-153. 10.1161/01.ATV.0000251502.88818.4b.PubMedCrossRef Koyama H, Shoji T, Fukumoto S, Shinohara K, Emoto M, Mori K, Tahara H, Ishimura E, Kakiya R, Tabata T, et al: Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol. 2007, 27: 147-153. 10.1161/01.ATV.0000251502.88818.4b.PubMedCrossRef
Metadata
Title
Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD
Authors
Poornima Gopal
Niki L Reynaert
Jean L J M Scheijen
Casper G Schalkwijk
Frits M E Franssen
Emiel F M Wouters
Erica P A Rutten
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2014
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-15-24

Other articles of this Issue 1/2014

Respiratory Research 1/2014 Go to the issue